Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience
Leuk Lymphoma
.
2022 Nov;63(11):2691-2695.
doi: 10.1080/10428194.2022.2086250.
Epub 2022 Jun 10.
Authors
Masuho Saburi
1
,
Masanori Sakata
1
,
Hiroyuki Takata
1
,
Yasuhiko Miyazaki
1
,
Katsuya Kawano
2
,
Hitohiro Sasaki
3
,
Miyuki Abe
3
,
Kazuhiro Kohno
3
,
Yasuhiro Soga
4
,
Kentaro Nagamatsu
5
,
Keiji Ono
5
,
Toshiyuki Nakayama
3
,
Eiichi Ohtsuka
1
Affiliations
1
Department of Hematology, Oita Prefectural Hospital, Oita City, Japan.
2
Department of Clinical Laboratory Technology, Oita Prefectural Hospital, Oita City, Japan.
3
Department of Hematology, Oita Kouseiren Tsurumi Hospital, Japan.
4
Department of Clinical Laboratory, Oita Kouseiren Tsurumi Hospital, Japan.
5
Department of Hematology, Almeida Memorial Hospital, Oita, Japan.
PMID:
35687847
DOI:
10.1080/10428194.2022.2086250
No abstract available
Publication types
Letter
MeSH terms
Aged
Disease-Free Survival
Humans
Leukemia, Plasma Cell* / diagnosis
Leukemia, Plasma Cell* / drug therapy
Retrospective Studies
Treatment Outcome